Biomedicine & Pharmacotherapy

Oncology Pharmacotherapy

Oncology pharmacotherapy focuses on the development and application of therapeutics to treat cancer by targeting molecular pathways, tumor microenvironments, and immune responses. Traditional chemotherapeutics, targeted small molecules, monoclonal antibodies, checkpoint inhibitors, and combination regimens are central to treatment strategies. Current challenges include drug resistance, tumor heterogeneity, off-target toxicity, and limited efficacy in certain cancer subtypes. Emerging trends involve precision oncology using genomic, transcriptomic, and proteomic profiling to identify actionable mutations and guide individualized therapy. Advances in immunotherapy, including chimeric antigen receptor T cells, bispecific antibodies, and therapeutic vaccines, enhance anti-tumor immunity. Nanotechnology-based drug delivery, antibody-drug conjugates, and prodrug strategies improve targeting, reduce systemic toxicity, and enhance bioavailability. Adaptive clinical trials, real-world evidence collection, and biomarker-driven endpoints are increasingly applied to evaluate treatment efficacy and optimize regimens. Integration of molecular diagnostics, computational modeling, and pharmacogenomics informs treatment selection and predicts therapeutic response. Challenges such as managing adverse effects, balancing efficacy with quality of life, and addressing socioeconomic and accessibility disparities remain significant. Oncology pharmacotherapy combines molecular insights, innovative therapeutic modalities, and precision medicine to improve patient outcomes, reduce toxicity, and develop personalized treatment strategies for complex and heterogeneous malignancies.